Epigenetic modulators as therapeutic targets in prostate cancer

Detalhes bibliográficos
Autor(a) principal: Pinho dos Santos Graça, Maria Inês
Data de Publicação: 2016
Outros Autores: Pereira-Silva, Eva, Henrique, Rui, Packham, Graham, Crabb, Simon J., Jerónimo, Carmen
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.22/9336
Resumo: Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
id RCAP_1de9994ab7ef2a140ee8b4a4c10de23b
oai_identifier_str oai:recipp.ipp.pt:10400.22/9336
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Epigenetic modulators as therapeutic targets in prostate cancerProstate cancerDNMTiHistone modulatorsProstate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.BioMed CentralRepositório Científico do Instituto Politécnico do PortoPinho dos Santos Graça, Maria InêsPereira-Silva, EvaHenrique, RuiPackham, GrahamCrabb, Simon J.Jerónimo, Carmen2017-01-20T15:09:15Z20162016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/9336engGraça, I., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016). Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 8(1), 98. https://doi.org/10.1186/s13148-016-0264-81868-708310.1186/s13148-016-0264-8info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-27T01:48:11Zoai:recipp.ipp.pt:10400.22/9336Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:29:57.722274Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Epigenetic modulators as therapeutic targets in prostate cancer
title Epigenetic modulators as therapeutic targets in prostate cancer
spellingShingle Epigenetic modulators as therapeutic targets in prostate cancer
Pinho dos Santos Graça, Maria Inês
Prostate cancer
DNMTi
Histone modulators
title_short Epigenetic modulators as therapeutic targets in prostate cancer
title_full Epigenetic modulators as therapeutic targets in prostate cancer
title_fullStr Epigenetic modulators as therapeutic targets in prostate cancer
title_full_unstemmed Epigenetic modulators as therapeutic targets in prostate cancer
title_sort Epigenetic modulators as therapeutic targets in prostate cancer
author Pinho dos Santos Graça, Maria Inês
author_facet Pinho dos Santos Graça, Maria Inês
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
author_role author
author2 Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Politécnico do Porto
dc.contributor.author.fl_str_mv Pinho dos Santos Graça, Maria Inês
Pereira-Silva, Eva
Henrique, Rui
Packham, Graham
Crabb, Simon J.
Jerónimo, Carmen
dc.subject.por.fl_str_mv Prostate cancer
DNMTi
Histone modulators
topic Prostate cancer
DNMTi
Histone modulators
description Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
publishDate 2016
dc.date.none.fl_str_mv 2016
2016-01-01T00:00:00Z
2017-01-20T15:09:15Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.22/9336
url http://hdl.handle.net/10400.22/9336
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Graça, I., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016). Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 8(1), 98. https://doi.org/10.1186/s13148-016-0264-8
1868-7083
10.1186/s13148-016-0264-8
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799131395795189760

Registros relacionados